Research & Development
OraSure wins $8.6M BARDA contract to develop Ebola test
OraSure Technologies has received an $8.6 million U.S. Biomedical Advanced Research and Development Authority (BARDA) contract to develop a second-generation Ebola test on its OraQuick testing platform.
September 28, 2022
In a first for U.S., FDA clears OraQuick rapid Ebola test
The OraQuick Ebola rapid antigen test provides an initial diagnosis based on a test of proteins in blood from people living with the virus or from cadaveric oral fluid in those who have died from it. The FDA noted that any rapid and early diagnosis made with the OraQuick test "must be confirmed."
October 9, 2019
Microfluidic device could detect Ebola virus earlier
Developed by researcher Ke Du, PhD, at the Rochester Institute of Technology, the device uses clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing technology to monitor and detect RNA markers for Ebola, a highly contagious virus for which there are limited treatments. Individuals in areas where Ebola infections are common are often required to take a blood test before they can travel.
May 5, 2019
Page 1 of 1